目的：探讨珠海地区早产儿视网膜病变（retinopathy of prematurity，ROP）的患病情况及临床特点。方法：回顾分析珠海市妇幼保健院2009年5月至2018年12月 5 473 例（10 946 只眼）早产儿的眼病筛查资料。结果：共筛查出 185 例（370 眼）患有不同程度的 ROP，患病率为 3.38%。33 例（66 眼）需要治疗，占 17.84%。低出生体重组出生孕周为 26～31，32～33，34～36的 ROP 患儿分别为 133，13，9 例，ROP 发病率分别为 14.9%，1.4%，1.3%，差异具有统计学意义（P < 0.05）。高出生体重组出生孕周为 26～31，32～33，34～36 的 ROP 患儿分别为 1，5，24例，ROP 发病率分别为 7.1%，1.1%，1.0%，差异无统计学意义（P > 0.05）。33 例严重 ROP 患儿（需要干预治疗的 ROP）中，低出生体重组出生孕周为 26～31，32～33，34～36 的严重ROP患儿分别为 29，3，1 例，发病率分别为 3.2%，3%，0.1%，差异具有统计学意义（P < 0.05）。高出生体重组无严重 ROP 患儿。结论：珠海地区近十年的早产儿 ROP 患病率为 3.38%，出生体重和胎龄是 ROP 发病的危险因素。严重ROP患儿的出生体重均 <2 000 g。

Objective: To investigate the clinical characteristics of retinopathy of prematurity (ROP) in Zhuhai. 

Methods: The eye screening data for 5,473 (10,946 eyes) premature infants born from May 2009 to December 2018 in the Maternal and Child Health Hospital of Zhuhai were retrospectively analyzed.

Results: In the 5 473 premature babies examination, 185 cases (3.38%) were detected with different degrees of ROP. The number of cases requiring treatment was 33 (17.84%). In the low birth weight group, the ROP patients with 26–31, 32–33, and 34–36 weeks were 133 (14.9%), 13 (1.4%), and 9 (1.3%), respectively; the difference was statistically significant (P < 0.05). In the high birth weight group, the ROP patients with birth weeks of 26–31, 32–33, and 34–36 were 1 (7.1%), 5 (1.1%), and 24 (1.0%), respectively; the difference was not statistically significant (P > 0.05). Among the 33 children with severe ROP (requiring intervention treatment), there were 29 (3.2%), 3 (3%), and 1 (0.1%) with birth weeks of 26–31, 32–33, and 34–36, respectively, in the low birth weight group; the difference was statistically significant (P < 0.05). The severe ROP was 0 in the high birth weight group.

Conclusion: The prevalence of ROP in premature infants is 3.38% in the past decade in Zhuhai. Birth weight and gestational age are risk factors for ROP. The birth weight of infants with severe ROP is less than 2 000 g.

目的：观察和分析儿童眼科门诊就诊的屈光不正 3～7 岁患儿，有早产史和足月产史的患儿的屈光不正的特点和差异。

方法：屈光不正 179 例（358 眼），分为 2 组：早产史者 51 人，足月产者 128 人。1％阿托品眼膏散瞳进行视网膜带状光剪影验光。

结果：足月儿的屈光不正患儿中，以远视多见，占 157／256 眼（61.3％），对比有早产儿屈光不正的远视发病 25／102（24.5％），差异有统计学意义（P < 0.05）。有早产儿屈光不正中，以散光发病为主，占 81／102 眼（79.4％），尤以高度散光、混合散光多见，相对与足月儿，其散光发病，高度散光发病和混合散光发病眼数的差异均有显著性（P < 0.05）。

结论：散光，尤其是高度散光、复杂的混合散光是有早产儿童视力低下的重要原因。临床上散光与弱视的形成关系密切相关，因此不能忽略早产儿童视力发育，最早可提前到 2 岁即可进行屈光筛查。

Purpose: To observe the abnormal refractive state and clinical characteristics in preterm and full-term children of the Department of Pediatric Ophthalmology.

Methods: The ocular refraction status of 358 eyes in 51 preterm and 128 full-term children were checked by retinoscopy in dilated pupil after being used atropine eye drops.

Results: There were 157 eyes with hyperopia accounting for 61.3% in preterm children, and 25 eyes with hyperopia accounting for 24.5% in full-term children. The main type of refractive errors in preterm children is astigmatism, especially in high astigmatism and mixed astigmatism. The morbidity of astigmatism, hyper astigmatism, and mixed astigmatism in preterm children is higher than that in full-term children.

Conclusion: Astigmatism, especially high astigmatism and complex mixed astigmatism, are important reasons for low vision in preterm children. Clinically, there is a close relationship between astigmatism and amblyopia. Therefore, the visual development of preterm children should not be ignored, and refractive screening could be brought forward to two years old.

目的：探讨口服25%葡萄糖减轻早产极低出生体重儿在第一次早产儿视网膜病眼底检查时的疼痛 的效果。方法：选取2014年9月至2015年8月在广东省妇幼保健院NICU住院的早产极低出生体重儿，随机分为观察组和对照组，观察组在进行第一次早产儿视网膜病眼底检查前2 min，给予25% 葡萄糖溶液1mL口服；对照组未用任何安慰剂。两组患儿眼底检查后分别进行新生儿疼痛量表的 评估。结果：观察组患儿眼底检查后疼痛评分低于对照组(P<0.001)。结论：眼底检查前2 min口服25%葡萄糖溶液1 mL是缓解早产儿视网膜病检查引起的疼痛的有效措施。

Objective: To explore the analgesic effect of oral glucose 25% on preterm and very low birth weight infants for the first time of fundus examination for retinopathy screening. Methods: Cases of preterm and very low birth weight infants in Guangdong Women and Children’s Hospital NICU from February 2014 to January 2015 were randomly divided into observation group and control group. The observation group was given 1 mL of 25% glucose solution by oral 2 min before the first time of retinopathy screening. The control group was given nothing. Pain was evaluated using the Neonatal Infant Pain Scale immediately after the fundus examination in both groups. Results: The NIPS of the observation group was lower than that of the control group (P<0.001). Conclusion: 1 mL of 25% glucose solution given 2 min before fundus examination for retinopathy of prematurity by oral was an effective measure for pain relief.

结节性硬化症(tuberous sclerosis complex，TSC)是一种累及多系统的常染色体显性遗传病，早期呈单一表现，容易漏诊、误诊，以眼部症状为首发特征的新生儿期病例少有报道。本文报告1例早产男婴，出生后1 d眼底筛查发现右眼视网膜散在多个灰白色半透明隆起灶及脱色素斑，回溯胎儿期超声心动图异常高度怀疑TSC，进一步行头颅MRI检查及家族基因检测，在新生儿期明确了这一诊断。

Tuberous sclerosis complex is a multisystemic disease with an autosomal dominant inheritance pattern. Missed diagnosis and misdiagnosis are common for patients with single manifestation in the early stage. There are few documented neonatal cases with ocular symptoms as primary presentation. Here we report a newborn boy presented with retinal hamartoma, retinal achromic patch, fetal cardiac rhabdomyoma and subependymal nodules.Subsequent genetic tests confirm a diagnosis of TSC.

目的：观察视网膜激光光凝术(laser photocoagulation，LP)及玻璃体腔注射雷珠单抗(intravitreal ranibizumab，IVR)对病变位于II区的阈值前病变1型早产儿视网膜病变(retinopathy of prematurity，ROP)的疗效。方法：收集2015年10月至2019年12月厦门市儿童医院收治的病变位于II区的阈值前病变1型44例(81眼)。根据手术方式分为LP组、IVR组。观察各组术后病变消退、视网膜血管化情况、全身及眼部并发症，分析不同手术方式的效果。结果：LP组20例(37只眼)行视网膜激光光凝治疗，术后未出现复发，首次治愈率100%；术后(3.42±1.57)周病情控制，术后(9.84±4.75)周可观察到周边视网膜血管化。IVR组24例(44只眼)注射雷珠单抗，39只眼行单次手术后病情控制，首次治愈率88.6%，5眼术后病情未控制。术后(2.95±2.58)周病情控制，术后(14.19±4.95)周可观察到周边视网膜血管化。两组手术方式首次治愈率、视网膜血管化时间差异有统计学意义(P<0.05)。结论：视网膜LP及IVR治疗病变位于II区的阈值前病变1型均有较好疗效，IVR复发率较高，手术方式的选择需慎重。

Objective: To observe the efficacy of laser photocoagulation (LP) and intravitreal ranibizumab (IVR) injection in the treatment of type 1 prethreshold retinopathy of prematurity (ROP) with lesions located in zone II. Methods:Forty-four patients (81 eyes) with type 1 prethreshold retinopathy of prematurity with lesions located in zone II staying in our hospital from October 2015 to December 2019 were collected and divided into LP group and IVR group according to the operation method. Through observation of the postoperative disease involution, retinal vascularization, systemic and ocular complications in each group, the effects of different surgical methods were analyzed. Results: In LP group, 20 patients (37 eyes) underwent retinal laser photocoagulation treatment, with no recurrence occurred after the operation; the cure rate after the first operation was 100%; the disease was controlled at (3.42±1.57) weeks after the operation; and peripheral retinal vascularization was observed at (9.84±4.75) weeks after the operation. In IVR group, 24 patients (44 eyes) were injected with ranibizumab; 39 eyes were under control after a single operation; the cure rate after the first operation was 88.6%; and 5 eyes were not under control after surgery. The disease was controlled for an average of (2.95±2.58) weeks after operation; peripheral retinal vascularization was observed at (14.19±4.95) weeks after operation; there were statistically significant differences in the cure rate after the first operation and retinal vascularization time between the two groups. Conclusion:Retinal laser photocoagulation and IVR have good effects in the treatment of type 1 prethreshold retinopathy of prematurity with lesions located in zone II. However, the recurrence rate using IVR is relatively high. Therefore,the surgical method needs to be cautious and still requires clinical observation.

目的：观察玻璃体腔内注射不同剂量康柏西普治疗早产儿视网膜病变(retinopathy of prematurity，ROP)的疗效以及术后的眼压变化。方法：前瞻性随机对照研究。将2018年1月1日至2021年6月30日在厦门市妇幼保健院确诊为Ι型阈值前期ROP、阈值期ROP、急进性ROP(aggressive ROP，A-ROP)的患儿纳入研究。随机分为减量组和常量组，分别玻璃体腔注射10 mg/mL康柏西普注射液0.015 mL(含康柏西普0.15 mg)和0.025 mL(含康柏西普0.25 mg)。测量并记录注射前5min、注射后5min、30min、1h、12h及24 h的眼压情况。术后1周开始随访眼底情况。疗效评价分为一次治愈、复发和加重。结果：共49例98眼纳入研究，常量组27例54眼，一次治愈成功率79.6%(43/54)，复发率16.7%(9/54)，加重率3.7%(2/54)；减量组2 2例44眼，一次治愈成功率68.2%(30/44)，复发率27.3%(12/44)，加重率4.5%(2/44)；两组间差异无统计学意义(χ 2=1.672，P=0.196)。治疗前5min两组眼压差异无统计学意义(P=0.494)；注药后5 min、1 h、12h两组眼压差异有统计学意义(均P<0.05)；注药后24 h两组间的眼压差异无统计学意义(P=0.101)。常量组注药前5 min和注药后24 h眼压差异有统计学意义(P=0.03)，减量组注药前5 min和注药后24h眼压差异无统计学意义(P=0.84)。结论：减量剂量康柏西普(0.15mg)治疗ROP有效，疗效与常规剂量(0.25 mg)相近，且术后眼压升高幅度较低，更快恢复至术前水平，更安全。

Objective: To evaluate the effectiveness of intravitreal injection of various doses of conbercept in the treatment of retinopathy of prematurity (ROP) and change of intraocular pressure (IOP) after operation. Methods: It was a prospective randomized controlled study. Children who were diagnosed with pre-threshold ROP, threshold phrase ROP, and aggressive ROP (A-ROP) in Xiamen Maternity and Child Healthcare Hospital from January 1, 2018 to June 30, 2021 were included in the study. The children were randomly divided into a reduction group and a constant group, and received intravitreal injection of10 mg/mL conbercept at 0.015 mL (containing 0.15 mg of conbercept) and 0.025 mL (containing 0.25 mg of conbercept) respectively. IOP was measured and recorded 5 min before injection, 5 min, 30 min, 1 h, 12 h and 24 h after injection. The fundus condition was followed up 1 week after the operation. The efficacy evaluation is divided into one cure, recurrence and exacerbation. Results: A total of 98 eyes of 49 cases were included in thestudy. For 27 cases of 54 eyes in the constant group, the one-time cure success rate was 79.6% (43/54), the recurrence rate was 16.7% (9/54), and the exacerbation rate was 3.7% (2/54). In the reduction group, there were 22 cases (44 eyes). The one-time cure success rate was 68.2% (30/44), the recurrence rate was 27.3% (12/44), and the exacerbation rate was 4.5% (2/44). There was no significant difference between the two groups (χ2=1.672,P=0.196). There was no significant difference in IOP between the 2 groups 5 min before treatment (P=0.494). There were statistically significantdifferences in IOP between the 2 groups at 5 min after injection, 1 h after injection, and 12 h after injection (all P<0.05). There was no difference in IOP between the two groups 24 h after injection (P=0.101). There was a statistically significant difference in IOP between 5 min before and 24 h after injection in the constant group (P=0.03), and there was no significant difference in IOP between 5 min before and 24 h after injection in the reduction group (P=0.84). Conclusion: Reduced dose of conbercept (0.15 mg) is effective in the treatment of ROP, and the efficacy is similar to that of conventional dose (0.25 mg). The reduction can help lower the increase of postoperative IOP, returning to the preoperative level more rapidly and safely.

目的：研究早产儿视网膜病变患儿经不同治疗措施后屈光状态的改变。方法：将72例(127眼)早产儿视网膜病变患儿按治疗方式分为3组：激光光凝组、注药(抗血管内皮生长因子药物)组和自然消退组。并于治疗前，治疗后1、4、7、12个月对其进行睫状肌麻痹检影验光，对比分析3组的球镜和等效球镜的差异。结果：在治疗后1、4、7及12个月，三组患儿的球镜度和等效球镜度的差异有统计学意义(P<0.05)：注药组的球镜和等效球镜小于自然退化组及激光组(均P0.05)。治疗后12个月时激光光凝组、注药组和自然消退组近视发生率分别是2.4%、7.8%和2.0%，差异无统计学意义(P=0.356)。结论：经不同治疗措施的ROP患儿近视发生率无明显差异，但经玻璃体腔注射抗VEGF药物的ROP患儿正视化进程更快。

Objective: To observe the changes of refractive statues in infants with retinopathy of prematurity retinopathyof prematurity (ROP) after different treatments. Methods: According to different treatment methods, 72 cases(127 eyes) of infants with ROP were divided into 3 groups: laser photocoagulation group, intravitreal injectionof anti-vascular endothelial growth factor (VEGF) drugs group and natural regression group. Their sphere andspherical equivalent were measured by retinoscopy optometrist after the ciliary muscles paralyzed. The data beforetreatments and 1, 4, 7 and 12 months after treatments were recorded and analyzed. Results: The differences ofsphere and spherical equivalent among three groups were statistically significant: intravitreal injection of VEGFdrugs group was lower than natural regression group and the laser photocoagulation group, but there was no significant difference between natural regression group and laser photocoagulation group. Incidence of myopiaof laser photocoagulation, intravitreal injection of VEGF drugs, natural regression group were 2.4%, 7.8%, 2.0%,which was not statistically significant. Conclusion: There was no significant difference about the incidence rate ofmyopia among the three groups, but the emmetropization in infants with ROP after intravitreal injection of anti-VEGF drugs might be faster in the future.